Metastasis-Directed Therapy in Prostate Cancer. Why, When, and How?

Area of Science:

• Oncology
• Radiation Oncology
• Urology

Background:

• Metastatic prostate cancer is a significant health challenge with limited curative options.
• Systemic therapies are the current standard but do not offer a cure.
• Metastasis-directed therapy (MDT) is an emerging strategy for specific patient groups.

Purpose of the Study:

• To review the rationale behind using metastasis-directed therapy (MDT) for prostate cancer.
• To discuss the potential benefits of stereotactic ablative radiotherapy (SABR) in this context.
• To outline practical considerations for implementing MDT with SABR.

Main Methods:

• Review of existing literature on metastasis-directed therapy and stereotactic ablative radiotherapy for prostate cancer.
• Analysis of the current evidence supporting MDT with SABR for low-volume metastatic disease.
• Discussion of clinical trial data and expert opinion.

Main Results:

• MDT with SABR shows promise in managing oligometastatic prostate cancer.
• Potential benefits include improved local control and possibly prolonged survival.
• Patient selection and treatment planning are critical for successful outcomes.

Conclusions:

• MDT with SABR is a viable complementary treatment for select patients with metastatic prostate cancer.
• Further research is needed to optimize patient selection and treatment protocols.
• This approach represents an evolving paradigm in advanced prostate cancer management.